Valdés RE, Camps AMC, Escalona FJ

Language: Spanish
References: 34
Page: 116-126
PDF size: 113.22 Kb.

ABSTRACT

Objective: to determine how often insulin for people with type 2 diabetes mellitus is indicated in Granma province, and to determine the associated factors with the indication for this treatment.
Methods: a cross-sectional descriptive study of 520 type 2 diabetic patients admitted to the Diabetic Care Center of Bayamo, Granma, from September 2011 to June 2013. Patients were divided into two groups: those with insulin therapy with and those with no insulin therapy.
Results: 308 patients (59.2 %) had insulin treatment. 156 (30 %) out of them used it continuously and 152 (29.2 %) had it briefly. The percentage of patients with insulin treatment significantly increased, increasing the duration of diabetes (p= 0.0000) as well. Cases with insulin treatment had a significantly lower body mass rate than those who did not use it (p= 0.0000). The presence of microvascular complications of diabetes is notoriously associated with the use of insulin (p= 0.0000).
Conclusions: the majority of type 2 diabetics in our country need insulin to control it and its use is closely related to the duration of diabetes, body mass index, blood glucose levels, and the presence of vascular complications of this disease.

REFERENCES

1. De Fronzo RA. From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773-94.

2. American Diabetes Association. Standards of Medical Care in Diabetes 2007. Diabetes Care. 2007;30:S4-41.

3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-53.

4. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193-203.

5. Canadian Diabetes Association. Clinical Practice Guidelines for the prevention and management of diabetes in Canada. Can J Diabetes. 2008;32(Suppl 1):S1-201.

6. AACE/ACE Consensus Statement. Statement by an American Association of Clinical Endocrinologist/American College of Endocrinology Consensus Panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15:540-59.

7. República de Cuba. Anuario Estadístico de Salud 2006. La Habana: MINSAP-DNE; 2006.

8. República de Cuba. Anuario Estadístico de Salud 2011. La Habana: MINSAP-DNE; 2011.

9. World Health Organization (WHO). Definition and classification of diabetes mellitus and complications. Report of WHO consultation. Part 1: Diagnosis and classification of Diabetes mellitus. World Health Organization. Department of Noncommunicable Desease Surveillance. Geneva, 1999.

10. Seventh Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JMCV). Hypertension. 2003;42:1206-52.

11. Worl d Health Organization (WHO). Expert Committee Phycal Status. The use and interpretation of anthropometry. Geneva. WHO Technical Report Serie No. 854;1995.

12. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP), Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.

13. L´Esperance FA. Diabetic retinopathy. Ophtalmic Laser Fotocoagulation, photoradiation and sugery. Diabetic Retinopathy In: L' Esperance FA (Jr). St Louis- Toronto-Londres: Ed. Mosby; 1983. P. 75-85.

14. Ito H, Harano Y, Suzuky M, Hattori y, Takeuchi M, Inada H, et al. Risk factor analyses for macrovascular complication in non obese NIDDM patients multiclinal study for diabetic macroangiopathy. Diabetes. 1996;45 (Suppl 3):519-23.

15. Schettler G, Nüssel E. Cholesterol CHOP-PAP. Arb Med Loz Med Präv Med. 1975;10:25.

16. Trinder P. Determination of glucose in blood using glucose oxidase with on alternative oxigen acceptor. Clin Biochem. 1996;11(2)24-7.

17. Primer consenso cubano de dislipoproteinemias: Guía para la prevención, detección, diagnóstico y tratamiento. Rev Cubana Endocrinol. 2006;17(4):1-31.

18. Valenciaga Rodríguez JL, Díaz Díaz O, Domínguez Alonso E. Tratamiento de la diabetes mellitus tipo 2 en el municipio de Güines, año 2002: Análisis con énfasis en la terapia medicamentosa. Rev Cubana Endocrinol [revista en la Internet]. 2003 Ago [citado 6 Ene. 2014];14(2). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-2953200300- 0200005&lng=es

19. Wright A, Burden AC, Paisey RB, Cull CA, Holman RR. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care. 2002;25:330-6.

20. Nelson SE, Palumbo PJ. Addition of insulin to oral therapy in patients with type 2 diabetes. Am J Med Sci. 2006;331:257-63.

21. Inzucchi SE, Bergenstal RM, Buse JB, Diamnt M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patien centered approach: position estatement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364-79.

22. Ortega Millan C, Fornoz Perez JA, Gracia Mayor R, Menéndez Torre E. Diabetología. Tema de actualidad. Triple terapia en diabetes tipo 2: revisión sistemática de la evidencia disponible. Avances en Diabetologia. 2010;26:276-80.

23. Lingvay I, Legendre JL, Kaloyanova PF, Zhang S, Adams-Huet B, Raskin B. Insulin based versus triple oral for newly diagnosed type 2 diabetes: Which is bether? Diabetes Care. 2009;32:1789-95.

24. Chow CC, Tsang LW, Sorensen JP, Cockram CS. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients. Diabetes Care. 1995;18:307-14.

25. Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Jarvinen H. Comparison of basal insulin added to oral agents versus twice daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care. 2005;28:254-9.

26. Donath MY, Ehses JA, Maedler K, Schumann M, Ellingsgaard H, Eppler E, et al. Mechanisms of -cell death in type 2 diabetes. Diabetes. 2005;54 Suppl 2:S108-13.

27. Matthews DR, Cull CA, Stratton IM, Holman RR, Turner RC. UKPDS 26: Sulphonylurea failure in non-insulin dependent diabetic patients over six years. Diabet Med. 1998;15:297-303.

28. Sender Palacios MJ, Vernet Vernet M, Larrosa Sáez P, Tor Figueras E, Foz Sala M. Características sociodemográficas y clínicas de una población de pacientes con diabetes mellitus. Aten Primaria. 2002;29:474-80.

29. Documento de posición de Sociedades de Diabetes y Endocrinología de América Latina sobre el tratamiento de la diabetes tipo 2. Grupo de trabajo ALAD. Revista de la Asocición Latinoamericana de Diabetes. 2009;17(2):69-78.

30. Martínez-Castelao A, Górriz JL, Sola E, Morillas C, Jover A, Coronel F, et al. A propósito de las discrepancias entre documentos de consenso, guías de práctica clínica y normativa legal en el tratamiento de la diabetes tipo 2. Nefrología (Madrid). 2012;32(4):0211-95.

31. Shaw JS, Wilmot RL, Kilpatrick ES. Establishing pragmatic estimated GFR thresholds to guide metformin prescribing. Diabet Med. 2007;24:1160-3.

32. Scornamiglio R, Avogaro A, Kreutzenberg SV, Negut C, Palisi M, Ba-golin E, et al. Effects of treatment with sulfonylurea drugs or insulin on ischemia-induced myocardial dysfunction in type 2 diabetes. Diabetes. 2002;51:808-12.

33. Lee TM, Chou TF. Impairment of myocardial protection in type 2 diabetic patients. J Clin Endocrinol Metab. 2003;88:531-7.

34. Hundal RS, Inzucchi SE. Metformin: new understandings, new uses. Drugs. 2003;63:1879-94.